Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PTI-808, PTI-801, and PTI-428 Combination in Cystic Fibrosis
NCT03500263Phase 2Completed
- Sponsor
- Proteostasis Therapeutics
- Start
- Jan 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dirocaftor, Posenacaftor and nesolicaftor in cystic fibrosis (CF) (6 arms), sponsored by Proteostasis Therapeutics. Primary endpoint: Safety and tolerability measured by adverse events and clinical assessments at Day 21. Started Jan 2018; status: completed.
02
Drugs
dirocaftorPosenacaftornesolicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03500263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03500263.